ClinicaliQ Trial Snapshot
- Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia — Recruiting • Phase II • NCT07033481.
- Neflamapimod was tested for safety and effectiveness in patients with a progressive language disorder affecting speech fluency.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA. Conditions: Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Interventions: Neflamapimod, Placebo Lead Sponsor: EIP Pharma Inc Planned Enrollment: 20 participants